Emapalumab Prophylaxis of Bispecific T-Cell Engagers (BiTEs) Associated CRS and ICANS
NCT07567014
·
clinicaltrials.gov ↗
PHASE2
Phase
NOT_YET_RECRUITING
Status
60
Enrollment
OTHER
Sponsor class
Conditions
Multiple Myeloma
Large B-cell Lymphoma (LBCL)
Interventions
DRUG:
Emapalumab
Sponsor
NYU Langone Health